文献速递消化系统肿瘤

Amivantamab单药治疗化疗难治性RAS/BRAF野生型转移性结直肠癌:OrigAMI-1 Ib/II期研究结果

Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.
PubMed 文献 · J Clin Oncol · 2026-04-21

OrigAMI-1是一项开放标签Ib/II期研究,评估Amivantamab单药在化疗难治性(既往2-3线)RAS/BRAF/EGFR胞外域野生型且无ERBB2/HER2扩增的转移性结直肠癌中的疗效。94例患者接受Amivantamab静脉给药(1050mg,≥80kg者1400mg)每2周一次。左侧队列A(无既往抗EGFR)ORR 29%(5/17),队列B(有既往抗EGFR)ORR 19%(10/54);右侧队列C ORR 22%(10/23)。中位缓解持续时间分别为9.0、6.1和9.8个月,中位无进展生存期分别为5.7、4.6和3.7个月。常见≥3级治疗相关不良事件为皮疹(7%)、痤疮样皮炎(4%)和低白蛋白血症(4%)。

要点

  • Amivantamab单药在化疗难治性mCRC中显示持久抗肿瘤活性,无论既往是否使用抗EGFR治疗及原发肿瘤部位。
  • 左侧mCRC无既往抗EGFR者ORR 29%,有既往抗EGFR者ORR 19%;右侧mCRC ORR 22%。
  • 安全性谱与NSCLC中已知经验一致,≥3级治疗相关不良事件以皮疹、痤疮样皮炎和低白蛋白血症为主。

核心结论

  • Amivantamab单药在化疗难治性RAS/BRAF/EGFR胞外域野生型且无ERBB2/HER2扩增的mCRC中显示出有前景且持久的抗肿瘤活性,无论既往是否接受抗EGFR治疗及原发肿瘤部位。

研究设计与样本

  • OrigAMI-1(NCT05379595)是一项开放标签Ib/II期研究,评估Amivantamab单药在化疗难治性(既往2-3线)mCRC中的疗效。
  • 入组患者经中心确认RAS/BRAF/EGFR胞外域野生型且无ERBB2/HER2扩增,分队列A(左侧mCRC无既往抗EGFR)、B(左侧mCRC有既往抗EGFR)和C(右侧mCRC无论既往抗EGFR)。
  • 共94例患者接受Amivantamab静脉给药1050mg(≥80kg者1400mg)每2周一次,主要终点为RECIST v1.1评估的客观缓解率(ORR)。

主要发现

  • 中位随访11.9个月,中位年龄60岁,65%为男性,中位既往治疗线数2线,94%既往接受贝伐珠单抗。
  • 左侧队列A ORR 29%(5/17),中位缓解持续时间(DoR)9.0个月,中位无进展生存期(PFS)5.7个月。
  • 左侧队列B ORR 19%(10/54),中位DoR 6.1个月,中位PFS 4.6个月。
  • 右侧队列C ORR 22%(10/23;43%有既往抗EGFR),中位DoR 9.8个月,中位PFS 3.7个月。
  • 最常见≥3级治疗相关不良事件为皮疹(7%)、痤疮样皮炎(4%)和低白蛋白血症(4%);1例因治疗相关不良事件停用Amivantamab。

临床怎么用

  • 对于化疗难治性RAS/BRAF野生型mCRC,Amivantamab单药可作为潜在治疗选择,需关注皮疹和低白蛋白血症等不良事件。
  • Amivantamab联合化疗正在一线和二线mCRC的两项III期研究中进行探索。

局限性

  • 本研究为开放标签、非随机Ib/II期研究,样本量较小(共94例),各队列样本量有限。
  • 随访时间有限(中位11.9个月),疗效和安全性需更大规模研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Amivantamab, an EGFR-MET bispecific antibody with immune cell-directing activity, is approved in non-small cell lung cancer (NSCLC). Effective treatments are limited for chemorefractory metastatic colorectal cancer (mCRC). METHODS: OrigAMI-1 (ClinicalTrials.gov identifier: NCT05379595) is a phase Ib/II study evaluating amivantamab monotherapy in chemorefractory (2-3 prior lines) mCRC. Participants had centrally confirmed RAS/BRAF/EGFR ectodomain wild-type status, without ERBB2/HER2 amplification. Participants with left-sided mCRC without (cohort A) or with (cohort B) prior anti-EGFR antibody treatment, or right-sided mCRC (cohort C) regardless of prior anti-EGFR treatment, received intravenous amivantamab 1,050 mg (1,400 mg for ≥80 kg) once every 2 weeks. The primary end point was objective response rate (ORR) per RECIST v1.1. RESULTS: By October 31, 2024, 94 participants received amivantamab monotherapy (median follow-up, 11.9 months). The median age was 60 years, and 65% of participants were male, with a median of 2 prior lines (94%, prior bevacizumab). In left-sided cohorts, the ORR was 29% (5 of 17) in cohort A and 19% (10 of 54) in cohort B; the median duration of response (DoR) was 9.0 months and 6.1 months, and the median progression-free survival (PFS) was 5.7 months and 4.6 months, respectively. In the right-sided cohort, the ORR was 22% (10 of 23; 43% had prior anti-EGFR), the median DoR was 9.8 months, and the median PFS was 3.7 months. Most frequent treatment-related grade ≥3 adverse events (AEs) were rash (7%), dermatitis acneiform (4%), and hypoalbuminemia (4%). One participant discontinued amivantamab because of a treatment-related AE. CONCLUSION: Amivantamab monotherapy demonstrated promising, durable antitumor activity in chemorefractory mCRC, regardless of prior anti-EGFR therapy and the primary tumor location. The amivantamab safety profile in mCRC is consistent with experience in NSCLC. Amivantamab plus chemotherapy is currently being explored in two phase III studies in first-line and second-line mCRCs.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Oberstein PE, Hecht JR, Raghav K, et al. Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. J Clin Oncol. 2026. PMID: 42013403. doi:10.1200/JCO-25-02187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。